Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
Stopped 109MS415 ImPROve study was terminated due to patient enrollment challenges and feasibility . The decision was not a result of safety concerns.
Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Relapsing-Remitting Multiple Sclerosis
Interventions
Sponsor
Biogen